Sarepta and Catalent Expand Strategic Manufacturing Partnership with Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate
January 06, 2023
January 06, 2023
SOMERSET, New Jersey, Jan. 6 -- Catalent Inc., a pharma, biotech and consumer health company, issued the following news:
Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, and Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the signing of a commercial supply agreement for Catalent to manufacture delandistrogene moxeparvovec (SRP-9001), Sarepta . . .
Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, and Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the signing of a commercial supply agreement for Catalent to manufacture delandistrogene moxeparvovec (SRP-9001), Sarepta . . .